Overview of Zetamac

Property	Description
Active ingredient	Azithromycin (typically as Dihydrate)
Form	Tablets, Oral Suspension, Intravenous Injection
Pharmacological class	Azalide (subclass of Macrolide Antibiotics)
Common use	Treatment of bacterial infections
Origin	Semi-synthetic

What Type of Medicine is Zetamac (Azithromycin)?

Zetamac is a prescription-only medicine whose active ingredient is Azithromycin. This substance is formally classified as an antibiotic and antimicrobial agent, utilized specifically for treating bacterial infections. Azithromycin belongs to the macrolide family of drugs but is precisely designated as an azalide, distinguished by the unique 15-membered ring structure in its chemical makeup. This classification is vital to understanding its pharmacological profile. Azithromycin is used to treat various bacterial infections, including respiratory and ear infections.

Composition, Origin, and Available Forms

The core compound, Azithromycin Dihydrate, is a semi-synthetic substance, meaning it was chemically derived and modified from the naturally occurring macrolide antibiotic erythromycin. This structural change results in high tissue penetration and a prolonged half-life. For patient use, Azithromycin is available in several distinct pharmaceutical preparations, including conventional tablets for oral intake, and as an oral suspension (liquid) which is frequently prescribed for pediatric patients. It is also available for intravenous (IV) injection for more acute infections, ensuring broad applicability across various clinical scenarios.

How Does Azithromycin Generally Help the Body?

The general purpose of Azithromycin is to help the body fight infection by stopping the growth of harmful bacteria. Its primary action is that of a bacterial protein synthesis inhibitor. The drug works by binding to the 50S bacterial ribosomal subunit, which prevents the bacteria from creating the necessary proteins for survival. By halting the growth and reproduction of bacteria, the drug acts as a bacteriostatic agent. This interruption in growth limits the proliferation of the pathogen, allowing the patient's own immune system sufficient time to clear the remaining infection and resolve the bacterial illness.

Regulatory References

U.S. National Library of Medicine

What side effects are possible with Zetamac?

Possible Side Effects and Safety Information

The official regulatory safety profile for Azithromycin (Zetamac) classifies adverse reactions based on incidence and the body system affected. These classifications allow for a structured understanding of potential outcomes, strictly based on government documentation.

Frequency-Classified Adverse Reactions

The most frequently reported effects are primarily gastrointestinal. According to regulatory documents, diarrhea is classified as Very Common (occurring in ge 1/10 patients). Reactions classified as Common (> 1/100, < 1/10) include nausea, abdominal pain, vomiting, and headache. Rare reactions, occurring in less than 1 in 1,000 patients, include conditions like photosensitivity.

Serious Adverse Reactions and Systemic Risks

The medicine's safety documentation highlights several serious systemic risks, particularly affecting the cardiac and hepatobiliary systems. These serious adverse reactions are formally listed in regulatory warnings and precautions:

Cardiac Risks: The drug is associated with Prolongation of the QT interval, which can lead to a potentially fatal arrhythmia known as Torsades de Pointes.
Hepatotoxicity: Severe, potentially fatal Hepatic Failure and Fulminant Hepatitis have been reported.
Hypersensitivity Reactions: Rare but serious allergic responses include Anaphylaxis and severe dermatological conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
Gastrointestinal: The development of Clostridioides difficile-Associated Diarrhea (CDAD) is a documented risk.

Population-Specific Safety Considerations

Official labeling includes specific cautions for certain patient groups. For older adults, there may be an increased susceptibility to cardiac effects (QT prolongation), especially in those with pre-existing proarrhythmic conditions. Use requires caution in patients with severe renal impairment or significant hepatic disease. Furthermore, reports of Infantile Hypertrophic Pyloric Stenosis (IHPS) are noted in neonates (up to 42 days of life) treated with this medicine.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Zetamac

Overdose scope

Documented overdose presentations: Overdose of macrolide antibiotics, including azithromycin (Zetamac), has been officially associated with specific acute effects:

Reversible loss of hearing
Severe nausea, vomiting, and diarrhea

Physiological systems affected (as stated in label):

Gastrointestinal system
Special senses (hearing)

Dose-related or exposure-related factors (if applicable): The documented manifestations are linked to an overdose of macrolide antibiotics. Specific dose levels that define an overdose are not explicitly stated in the regulatory overdose section.

Population-specific overdose notes (if applicable): No population-specific risks (e.g., in pediatrics or geriatrics) are explicitly detailed within the official overdose management text.

Emergency-response statements (as written in official documents):

Gastric lavage may be indicated.
General supportive measures should be instituted as necessary.
Symptomatic treatment is required and should align with the patient’s clinical state.

When immediate medical help is required (label-derived phrasing only): Any suspected overdose requires prompt medical evaluation and the institution of general supportive measures and symptomatic treatment.

Overdose classifications (high-level)

Severity classification (as defined in official documents): Symptoms are described using terms such as severe (e.g., severe nausea/vomiting), but no formal severity grading system (e.g., Grade 3) is applied in the official text.

Regulatory basis (EMA / FDA / etc.): FDA (based on Prescribing Information for azithromycin products).

Overdose-context constraints (as defined in official documents): Hemodialysis or peritoneal dialysis is not expected to be useful in the event of an overdose due to the drug’s pharmacological properties.

Resulting overdose structure

Official overdose statements:

Overdose has been associated with reversible hearing loss, severe nausea, severe vomiting, and diarrhea.
Management includes general supportive and symptomatic measures, and consideration of gastric lavage.
Dialysis procedures (hemodialysis or peritoneal) are not considered effective for drug removal.

Connection to the overall overdose profile (2–4 sentences): The official regulatory documents characterize the overdose profile of Zetamac (azithromycin) primarily by acute, severe gastrointestinal symptoms and the risk of reversible hearing impairment, reflecting its class effects. Emergency management is defined as requiring symptomatic and supportive care, along with an explicit statement that standard dialysis methods are ineffective. The overall guidance stresses clinical support for the reported manifestations.

Therapeutic Uses of Zetamac

Zetamac is an antibiotic generally used in situations involving certain distressing symptoms that arise from bacterial infections. It is commonly applied across domains where additional symptomatic support is needed and is used to help manage associated discomfort. This medication is applied in addressing conditions like community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, strep throat, acute otitis media (middle ear infection), uncomplicated skin and skin structure infections, and specific bacterial sexually transmitted infections.

The medication helps address symptom clusters that may become intense or disruptive, including persistent cough, fever, localized pain, and difficulty breathing. This supportive relief may assist with maintaining functional stability when symptoms interfere with routine activities. It is relevant when supportive symptom management is appropriate, as it contributes to easing the overall symptom load.

“The treatment may help support patients during difficult episodes by easing distress and can contribute to improved day-to-day comfort during symptomatic periods.”

Quick Fact: Relevant for Managing Acute Inflammatory Symptoms

Zetamac is considered relevant for easing symptoms related to inflammatory or irritative states across multiple systems, and may help support the patient during episodes of heightened discomfort in both respiratory and localized infections.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Zetamac (Azithromycin)

This eligibility information is derived strictly from official government regulatory documents (e.g., FDA labeling) for the drug product Azithromycin.

Non-Eligibility (Contraindications)

Individuals must not use this medicine if they have a known hypersensitivity (allergic reaction) to Azithromycin, Erythromycin, or any other macrolide or ketolide class drug. Use is also contraindicated in patients with a prior history of cholestatic jaundice or hepatic dysfunction specifically associated with the previous use of Azithromycin.

Populations Requiring Special Consideration

Population/Condition	Eligibility Status
Pediatric Patients	Safety and effectiveness not established for infants under 6 months of age for most indications.
Liver Function	Contraindicated with history of Azithromycin-associated hepatic dysfunction.
Myasthenia Gravis	Use is limited as the medicine may exacerbate muscle weakness.
Severe Illness	Patients with moderate to severe pneumonia or risk factors (e.g., suspected bacteremia) are typically not recommended for treatment with the oral formulation.

Eligibility is defined by a history of specific adverse reactions to the drug class and by certain pre-existing conditions, which necessitate either absolute exclusion or careful clinical consideration.

What should I know about interactions with other medicines?

The interaction profile of Zetamac, which contains the active ingredient Azithromycin, is established by authoritative regulatory agencies based on pharmacokinetic (PK) and pharmacodynamic (PD) outcomes.

Formal Prohibitions and High-Risk Combinations

Co-administration with Ergot Derivatives (e.g., ergotamine) is formally prohibited due to the theoretical risk of ergotism. Furthermore, regulatory documents specify that Zetamac should not be co-administered with other medicinal products known to prolong the QT interval (e.g., Class IA and III antiarrhythmics), as this creates an additive PD risk for Torsades de pointes.

Pharmacokinetic and Exposure Alterations

The profile details several changes in drug exposure. Co-administration with Nelfinavir leads to a significant increase in Azithromycin's own peak plasma concentration (Cmax) and overall systemic exposure (AUC). Conversely, Antacids (containing aluminum or magnesium) reduce Azithromycin's Cmax by approximately 24%, requiring mandatory administration separation of at least one to two hours. Zetamac is associated with an increased risk of elevated plasma levels for P-glycoprotein substrates like Digoxin and the immunosuppressant Ciclosporin, requiring clinical monitoring.

Mechanism of Action

How Zetamac Works

Blocking the Bacterial Protein Factory

The primary action of Azithromycin is to interfere directly with susceptible bacteria by binding tightly to their 50S ribosomal subunit. This molecular binding blocks the exit tunnel where new proteins are being assembled, effectively halting the creation of necessary enzymes and structural components. The resulting inhibition of protein synthesis arrests the growth and replication of the pathogen, allowing the host immune system to engage the non-replicating microbial population.

️ Modulating Inflammatory Pathways

Azithromycin exerts a secondary mechanism by acting as an immunomodulator on host cells. It influences overactive inflammatory responses by reducing the production of specific pro-inflammatory signaling molecules (cytokines) and enzymes. This mechanism results in reduced accumulation and activity of inflammatory cells like neutrophils at the site of challenge, thereby influencing inflammatory signaling and modulating epithelial barrier function.

Understanding Mechanistic Limitations

The drug’s mechanism is constrained by bacterial mechanisms of resistance, most commonly through enzymatic modification of the 23S rRNA binding site or by activating dedicated efflux pumps that actively expel the drug. These biological changes reduce Azithromycin's access to its ribosomal target, limiting the effectiveness of the protein-synthesis-blocking mechanism.

Dosage and Administration Information

How to use Zetamac

Zetamac (Azithromycin) administration is officially approved through two distinct routes: oral (available as tablets and liquid suspension) and intravenous (IV) infusion. The IV route is typically reserved for initial therapy in specific acute cases.

The standard adult dosing regimen is structured as a short course of therapy, most commonly targeting a 1500 mg total dose, administered either as 500 mg once daily for three days, or a five-day sequence beginning with 500 mg on Day 1 followed by 250 mg once daily on Days 2 through 5. A single 1000 mg dose is also an approved regimen for certain specific infections.

Administration Conditions

The intake requirements are dependent on the pharmaceutical form. Standard oral tablets and suspension can be taken with or without food. However, the extended-release suspension form must be administered on an empty stomach—at least one hour before or two hours after a meal. Additionally, oral doses should not be taken simultaneously with antacids; an interval of approximately two hours is required. The IV formulation requires the powder to be reconstituted and subsequently diluted prior to use, which must occur as a slow infusion over a minimum of 60 minutes.

Special Population and Missed Dose Rules

For pediatric patients under 45 kg, dosing is strictly calculated on a weight-based basis (mg/kg) using the oral suspension. If a dose is missed, it should be taken as soon as remembered; however, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients must not take extra medication to compensate for a forgotten dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zetamac (Azithromycin)

Evidence for Use in Acute Respiratory and Ear Infections

The research base for Azithromycin was studied for use in common acute infections, such as Community-Acquired Pneumonia (CAP) and Acute Otitis Media (middle ear infection), primarily involves Randomized Controlled Trials (RCTs) and systematic reviews. Researchers monitored outcomes related to clinical status—including measurements of symptom evolution, such as changes in fever and cough—along with the eradication of bacteria and measurements of mortality over short- and intermediate-term follow-up periods.

Studies reported measurements of clinical outcomes that aligned with the patterns observed in research for other established treatments when used for these specific acute infections. In the context of CAP, comparative trials reported similar patterns of clinical status and measurements of hospital stay duration across different patient cohorts. However, these trials generally report group patterns, and research does not determine whether an individual will respond similarly.

Evidence for Use in Bronchitis and Throat/Skin Infections

The evidence base for Azithromycin in Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) and infections of the throat and skin has been evaluated through comparative clinical trials and meta-analyses. These studies examined adults experiencing episodic or acute changes in their chronic bronchitis symptoms, applying research to examine patient-reported experiences related to physical discomfort and bacteriological clearance from the site of infection.

Research highlights measurements of clinical outcome in the short-term that contributed to the broader evidence landscape for Azithromycin. What remains uncertain in the context of ABECB is the optimal duration of treatment for acute episodes. For both skin and throat infections, comparative evidence exploring significant differences against other drugs is often not available.

Research for Select Sexually Transmitted Infections

Azithromycin was evaluated in specific short-course Randomized Controlled Trials (RCTs) for certain urethritis and cervicitis infections, which are conditions characterized by fluctuating manifestations. Trials reported measurements of microbiological eradication for specific target organisms (e.g., C. trachomatis) following the typically single-dose regimen.

What remains uncertain is the applicability of research findings in the face of evolving patterns of resistance in certain sexually transmitted pathogens. Furthermore, the long-term outcomes reflecting daily functioning or activity level following treatment were not consistently measured in these short-term studies.

Long-Term Studies and What is Still Uncertain

While Azithromycin is typically used for short-course treatment, research has also explored its use over extended periods in specialized long-term RCTs for certain chronic inflammatory lung conditions like Chronic Obstructive Pulmonary Disease (COPD). These studies monitored outcomes related to changes in the frequency of exacerbations over a 6- to 12-month period in selected patient groups.

A continuing area of research is the potential for increased antimicrobial resistance that was associated with repeated or long-term use in some studies. Data for certain groups, such as infants younger than 6 months of age, remain insufficient compared to the general population.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Zetamac (FAQ)

Q: What is the difference between Zetamac and other similar drugs in the same class?

A: Zetamac (Azithromycin) is formally designated as an azalide, a subclass of macrolide antibiotics. According to official documents, this classification is due to its unique chemical structure, a 15-membered ring. This structure is associated with pharmacological properties like high tissue penetration and a prolonged half-life.

Q: How long does the effect of Zetamac last?

A: Official pharmacokinetic data highlights the drug's prolonged half-life, which supports the use of short-course treatment regimens. This property is associated with the active substance remaining in the body's tissues for an extended period.

Q: Can Zetamac be taken long-term?

A: The drug is typically prescribed for short-term treatment of acute bacterial infections. Official research has also examined its use over extended periods for treating certain chronic inflammatory lung conditions. Official documents note an association between repeated or long-term use and a potential for increased antimicrobial resistance in some studies.

Q: Are there any foods or drinks to avoid while taking Zetamac?

A: The standard oral tablets and suspension can be taken with or without food. However, the extended-release suspension form is described as being administered on an empty stomach. Additionally, regulatory documents require an interval of approximately two hours when taking this medicine with antacids that contain aluminum or magnesium.

Q: Is Zetamac safe for children?

A: The safety and effectiveness of the drug are not established for infants under 6 months of age for most indications. For older children, the prescribing information includes approved weight-based dosing. Official safety information also notes reports of Infantile Hypertrophic Pyloric Stenosis (IHPS) in neonates (up to 42 days of life) treated with this medicine.

Q: Why do some people refer to Zetamac as a 'new generation' drug?

A: The drug is a semi-synthetic derivative, meaning it was chemically modified from the older macrolide erythromycin. This modification created the azalide subclass, which is associated with different pharmacological properties, such as a different tissue distribution and a prolonged half-life.

Q: What is the shelf life of Zetamac?

A: The tablets must be stored at controlled room temperature and protected from heat and moisture. For the liquid oral suspension, official documents specify a stability of only 10 days after the powder is mixed, and any remaining liquid must be discarded after this period.

Q: Is Zetamac used to treat chronic conditions or only acute issues?

A: Regulatory research has examined the drug for both acute bacterial infections (such as pneumonia and ear infections) and for extended periods in selected patient groups with certain chronic inflammatory lung conditions. Therefore, its use has been studied in both acute and chronic contexts.

Q: Are there specific laboratory tests required while taking Zetamac?

A: Regulatory documents do not generally mandate routine laboratory tests for all patients. However, close monitoring of prothrombin time is required if the drug is taken with the anticoagulant Warfarin. Clinical monitoring is also necessary when the drug is taken with certain other drugs, such as Digoxin and Ciclosporin.

Q: Does Zetamac contain aspirin or ibuprofen?

A: The active ingredient in the medicine is Azithromycin. Official regulatory documents detail the composition, listing Azithromycin dihydrate and various inactive ingredients, but they do not list common pain relievers like aspirin or ibuprofen as components.

Q: Is it common to feel drowsy after taking Zetamac?

A: Official regulatory documents list headache and fatigue as Common adverse reactions (occurring in 1 out of 10 to 1 out of 100 patients). Dizziness is also listed as a possible side effect, which may be associated with a feeling of drowsiness.

Q: Is there a risk of dependence or withdrawal with Zetamac?

A: Official prescribing information does not contain specific warnings or precautions regarding dependence or withdrawal symptoms.

Q: Does Zetamac interact with alcohol?

A: Official regulatory documents do not list a formal drug-drug interaction between this medicine and alcohol. However, official information notes that alcohol consumption may contribute to an increase in common gastrointestinal side effects like nausea and vomiting.

Q: Can Zetamac be taken with common pain relievers like Tylenol?

A: Official documents indicate that the drug is not known to interact significantly with non-opioid pain relievers such as acetaminophen (Tylenol). However, co-administration of any medicine requires review of the complete prescribing information.

Q: Does Zetamac affect birth control pills?

A: Authoritative medical guidelines and regulatory reviews indicate that this medicine is not associated with reducing the effectiveness of hormonal birth control (e.g., pills, patches), unlike some other types of antibiotics.

Q: What should I know about taking Zetamac with supplements or vitamins?

A: Official safety information advises caution due to the limited established information regarding potential interactions with supplements or vitamins. Official regulatory documents indicate that there is not enough established information to confirm that complementary medicines or herbal remedies are safe to take with this drug.

Q: Can I use Zetamac if I have high blood pressure?

A: High blood pressure (hypertension) is not listed as a contraindication. However, the use of the drug is associated with a need for special consideration in patients with pre-existing conditions that may increase the risk of a prolonged QT interval, a serious cardiac effect.

Q: Is Zetamac safe for people with diabetes?

A: Diabetes is not listed in the official regulatory documents as a contraindication or a specific special caution for use with this medicine.

Q: What is the classification of Zetamac in terms of safety during pregnancy?

A: The Australian TGA classification for this drug is Category B1. The US FDA states that available data from published studies have not identified drug-related risks for major birth defects, miscarriage, or adverse outcomes. Official information states that use is described as necessary only if clearly needed.

Q: Can I take Zetamac while breastfeeding?

A: Official information confirms that Azithromycin is present in human milk. Regulatory documents recommend that caution should be exercised when the drug is administered to a nursing mother.

Q: Where can I find official regulatory information about Zetamac?

A: Official prescribing information is available directly from regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC), and the NIH/National Library of Medicine (DailyMed).

Q: Does Zetamac affect sleep patterns?

A: Regulatory documents list fatigue and headache as common side effects. Specific effects on sleep patterns, such as insomnia, are not commonly cited in the primary or serious adverse reaction sections.

Q: What should I do if a side effect seems unusual?

A: Official patient counseling information highlights the importance of contacting a healthcare provider if signs of a serious adverse reaction, such as severe diarrhea or heart rhythm changes, are observed. These serious effects include allergic reactions and liver problems.

Q: Is Zetamac known to interact with herbal remedies?

A: Official safety information advises caution due to the limited established information regarding potential interactions with herbal remedies. Regulatory documents indicate that there is not enough established information to confirm that complementary medicines or herbal remedies are safe to take with this drug.

Q: Is there a generic version of Zetamac available?

A: The drug is widely available in a generic version under its active ingredient name, Azithromycin. Generic availability is part of the official drug lifecycle information.

Q: What is the difference between the various strengths of Zetamac?

A: The medication is formally supplied in different strengths, typically as 250 mg tablets and 500 mg tablets, as well as in powder for oral suspension and intravenous forms. The available strengths are detailed in the official 'How Supplied' sections.

Q: Does Zetamac affect my ability to drive or operate machinery?

A: Due to the reported possibility of side effects such as dizziness or fatigue, regulatory documents advise that patients should be aware of how they react to the medication before driving or operating machinery. Caution is necessary until the individual response is known.

Q: Is Zetamac approved for use in Europe (EMA)?

A: The drug is authorized and regulated for use in Europe, as confirmed by the availability of the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) document.

Q: Is it normal to feel lightheaded when starting Zetamac?

A: The potential side effect of dizziness is listed in regulatory documents. Lightheadedness is a symptom often associated with dizziness, and if it occurs, it should be monitored.

Q: What if Zetamac does not seem to be working for me?

A: Patient information advises contacting a healthcare provider if the infection being treated does not improve or if symptoms worsen after starting the medication. It is important not to change the prescribed use without guidance.

Q: Is Zetamac considered a disease-modifying drug?

A: Official regulatory classification defines the drug as an azalide (macrolide antibiotic), which is used to treat bacterial infections by stopping the growth of bacteria. It is not classified as a disease-modifying drug.

Q: Can I take Zetamac if I have a history of depression or anxiety?

A: A history of depression or anxiety is not listed in the official regulatory documents as a contraindication or a specific special caution for use with this medicine.

Q: Is it mandatory to complete the full course of Zetamac?

A: Patient counseling information advises that it is important to take the medication exactly as prescribed and to complete the full course of therapy. This practice is noted to help ensure the intended clinical effect, even if symptoms begin to improve.

How should Zetamac be stored and disposed of?

How to Store and Dispose of Azithromycin (Zetamac)

Official storage conditions are strictly defined to maintain drug stability across all forms.

Storage Requirements

Azithromycin tablets must be stored at controlled room temperature, typically between 15°C and 30°C. The medication must be kept in its tightly closed container and protected from excessive heat and moisture.

Liquid oral suspension has a limited stability. After the powder is mixed, the suspension is stable for only 10 days. Any remaining liquid must be discarded after this period.

Handling and Disposal

The medicine must not be frozen. For child safety, the product must be kept out of the sight and reach of children.

Unused, expired, or leftover medicine should not be disposed of in household waste or by flushing down the toilet. Return the unused product to a pharmacist or designated collection point for proper environmental disposal, in accordance with local regulations.

Zetamac